Botswana Study of UC-781 Vaginal Microbicide
NCT00385554 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2012-08-16
Summary
This study will test the safety, side effects, and acceptability of two strengths of UC-781 gel when used by women and men in Botswana for two weeks.
Conditions
- HIV Infections
Interventions
- DRUG
-
UC-781 carbomer gel, 0.1% and 0.25%
Sponsors & Collaborators
-
CONRAD
collaborator OTHER -
Centers for Disease Control and Prevention
lead FED
Principal Investigators
-
Dawn K Smith, MD, MPH · BOTUSA/CDC
-
Christine K Mauck, MD, MPH · CONRAD
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
Countries
- United States
- Botswana
Study Locations
More Related Trials
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308046 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of SAVVY and HIV in Ghana
NCT00129532 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission
NCT00213083 ·Status: COMPLETED ·Phase: PHASE3
-
Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine
NCT01285141 ·Status: COMPLETED ·Phase: PHASE1
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308033 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology
NCT02527941 ·Status: COMPLETED ·Phase: PHASE1
-
An Expanded Safety Study of Dapivirine Gel 4759 in Africa
NCT00917891 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of BufferGel in Women
NCT00000927 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
NCT01490671 ·Status: WITHDRAWN ·Phase: PHASE2
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308007 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
NCT00303576 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
NCT00262106 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
NCT00799058 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
NCT01575405 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa
NCT00304668 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Rectal Safety and Acceptability Study of Tenofovir 1% Gel
NCT01232803 ·Status: COMPLETED ·Phase: PHASE1
-
An Expanded Safety Study of Dapivirine Gel 4789 in Africa
NCT00917904 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
NCT00074425 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men
NCT03412071 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males
NCT03218839 ·Status: COMPLETED ·Phase: NA
-
Trial of SAVVY Vaginal Gel and HIV in Nigeria
NCT00130078 ·Status: UNKNOWN ·Phase: PHASE3
-
A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium
NCT00309205 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of BufferGel and PRO 2000/5 Gel in Men
NCT00016536 ·Status: COMPLETED ·Phase: PHASE1
-
Cellulose Sulfate and HIV Transmission Among Women
NCT00153777 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy Study to Treat Bacterial Vaginosis
NCT01621399 ·Status: COMPLETED ·Phase: PHASE3